NeuBase Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NeuBase Therapeutics, Inc. - overview
Location
Pittsburgh, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2018 NeuBase Therapeutics, Inc. is a biotechnology company that develops gene silencing therapies with its synthetic antisense oligonucleotides. The company was founded by Mr. Dietrich A.
Stephan, Ph. D. , and has approximately 21 employees. In May 2004, The Company has become a publicly listed company on the NASDAQ stock exchange.
In January 2019, NeuBase Therapeutics, Inc. entered into a definitive merger agreement with Ohr Pharmaceutical, Inc. NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides.
Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's disease, myotonic dystrophy, and Familial Parkinson’s disease among others. The company generates revenue by offering the developed therapies to pharmaceutical companies. As of January 2021, NeuBase Therapeutics Inc. announces the acquisition of infrastructure, programs, and intellectual property from Vera Therapeutics, Inc.
The transaction is expected to close in the first calendar quarter of 2021.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Diagnostic Equipment, Therapeutic Devices
Website
www.neubasetherapeutics.com
Total Amount Raised
Subscriber access only
NeuBase Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.